Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan

MLA

Takayuki Ikezoe, et al. “Long-Term Follow-up of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab: Post-Marketing Surveillance in Japan.” International Journal of Hematology, vol. 115, Feb. 2022, pp. 470–80. EBSCOhost, https://doi.org/10.1007/s12185-022-03287-y.

APA

Takayuki Ikezoe, Hideyoshi Noji, Yasutaka Ueda, Yoshinobu Kanda, Shinichiro Okamoto, Kensuke Usuki, Takahisa Matsuda, Hirozumi Akiyama, Akihiko Shimono, Yuji Yonemura, Tatsuya Kawaguchi, Shigeru Chiba, Yuzuru Kanakura, Jun‑ichi Nishimura, Haruhiko Ninomiya, & Naoshi Obara. (2022). Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan. International Journal of Hematology, 115, 470–480. https://doi.org/10.1007/s12185-022-03287-y

Chicago

Takayuki Ikezoe, Hideyoshi Noji, Yasutaka Ueda, Yoshinobu Kanda, Shinichiro Okamoto, Kensuke Usuki, Takahisa Matsuda, et al. 2022. “Long-Term Follow-up of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab: Post-Marketing Surveillance in Japan.” International Journal of Hematology 115 (February): 470–80. doi:10.1007/s12185-022-03287-y.